Brief: Adamis Sends Letter To Stockholders Regarding Its Strategic Focus On Tempol As A Potentially Potent Treatment For Covid-19
28/06/2021 13:36
Adamis Pharmaceuticals Corp ADMP.O :
* ADAMIS SENDS LETTER TO STOCKHOLDERS REGARDING ITS
STRATEGIC
FOCUS ON TEMPOL AS A POTENTIALLY POTENT TREATMENT FOR COVID-19
* ADAMIS PHARMACEUTICALS - BELIEVES MAINTAINING BOARD
CONTINUITY
IS CRITICAL TO CONTINUING TO PURSUE PROGRESS RELATED TO TEMPOL
* ADAMIS PHARMACEUTICALS - PLAN TO BEGIN ENROLLING PATIENTS
IN
PHASE 2/3 CLINICAL TRIAL FOR TEMPOL IN Q3
Source text for Eikon: ID:nBw2dT75Fa
Further company coverage: ADMP.O
Recent news on DMK Pharmaceuticals
See all newsBrief: Dmk Pharmaceuticals Corp Says Ebrahim Versi Resigned As Chairman
Brief: ZMI Pharma Finalized Acquisition Of All Strategic Assets Necessary To Manufacture Zimhi From Dmk Pharma
Brief: DMK Pharmaceuticals Files For Chapter 11 Bankruptcy In The U.S. - Court Filing
Brief: Dmk Pharmaceuticals Regains Full Rights To Commercialize Zimhi
Brief: DMK Pharmaceuticals Regains Full Rights From US Worldmeds For Symjepi And Provides Corporate Update